

FULL TEXT LINKS



Editorial > [Neuro Oncol.](#) 2023 Feb 15;noad043. doi: 10.1093/neuonc/noad043.

Online ahead of print.

Phase 2 trials in the era of glioblastoma immunotherapy: New mechanisms of action, familiar challenges in trial design and tumor response assessment

[Stephen J Bagley](#)¹

Affiliations

Affiliation

- ¹ Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

PMID: 36789741 DOI: [10.1093/neuonc/noad043](#)

No abstract available

Comment on

[Targeting the IL4 Receptor with MDNA55 in Patients with Recurrent Glioblastoma: Results of a Phase 2b Trial.](#)

Sampson JH, Singh Achrol A, Aghi MK, Bankiewicz K, Bexon M, Brem S, Brenner A, Chandhasin C, Chowdhary S, Coello M, Ellingson BM, Floyd JR, Han S, Kesari S, Mardor Y, Merchant F, Merchant N, Randazzo D, Vogelbaum M, Vrionis F, Wembacher-Schroeder E, Zabek M, Butowski N.

[Neuro Oncol.](#) 2023 Jan 14;noac285. doi: 10.1093/neuonc/noac285. Online ahead of print.

PMID: 36640127

LinkOut – more resources

Full Text Sources

[Silverchair Information Systems](#)